Advair Diskus (Fluticasone and Salmeterol) Inhalation Powder

Advair Diskus is a combination inhaler that pairs fluticasone propionate, an inhaled corticosteroid, with salmeterol, a long-acting beta2-agonist (LABA), in a single dry-powder device. It is used for the regular, ongoing control of asthma and chronic obstructive pulmonary disease (COPD), not for treating a sudden attack. Understanding how the two ingredients work together helps explain why this inhaler is dosed the way it is and why it differs from quick-relief inhalers.

What Advair Diskus Is Used For

Fluticasone reduces the airway inflammation that underlies asthma, calming swelling and mucus production in the bronchial tubes over time. Salmeterol relaxes the smooth muscle around the airways for up to 12 hours per dose, keeping them open between administrations. Together, they are indicated for the maintenance treatment of asthma in patients 12 years and older, and pediatric asthma use is established from age 4 with strength-specific dosing. The 250 mcg/50 mcg strength is also indicated for the maintenance treatment of COPD, including chronic bronchitis with airflow limitation, in adults. Because salmeterol alone can increase the risk of serious asthma-related events, it is appropriate for asthma only when paired with an inhaled corticosteroid such as fluticasone, which is how this product is formulated.

How Advair Diskus Is Used

Advair Diskus is a breath-activated, multi-dose inhalation powder rather than a pressurized aerosol. Each use involves opening the device, sliding the lever to load a single dose, and inhaling forcefully and deeply through the mouthpiece; no spacer or coordinated priming spray is required. For asthma in patients aged 12 years and older, the usual regimen is one inhalation of the prescribed strength twice daily, about 12 hours apart. Children aged 4 to 11 years use one inhalation of the 100 mcg/50 mcg strength twice daily. For COPD maintenance in adults, the established regimen is one inhalation of the 250 mcg/50 mcg strength twice daily. Patients should not take more than one inhalation twice daily or change strengths without guidance from their prescriber.

Salmeterol may begin improving airflow within about 30 to 60 minutes, but Advair Diskus is not a rescue inhaler and does not relieve sudden breathlessness. The full benefit of regular anti-inflammatory treatment may take a week or longer to become apparent. A separate fast-acting bronchodilator should remain available when prescribed for sudden symptoms. Rinsing the mouth with water and spitting it out after each use helps reduce the risk of oral thrush and hoarseness associated with the inhaled corticosteroid component. Advair Diskus can be used without regard to meals, and the device does not allow partial-dose measurement.

Available Strengths and Package Options

We offer Advair Diskus in three strengths: 100 mcg/50 mcg, 250 mcg/50 mcg, and 500 mcg/50 mcg, each combining a fixed fluticasone dose with 50 mcg of salmeterol per inhalation. The 100 mcg/50 mcg strength is available from us in packs of 2 or 3 inhalers, while the 250 mcg/50 mcg and 500 mcg/50 mcg strengths are available in packs of 1, 2, 3, 4, or 5 inhalers, letting customers choose a quantity that matches a shorter supply or a longer maintenance schedule.

Advair Diskus, Wixela Inhub, and Other Combination Inhalers

A generic equivalent of Advair Diskus is marketed in the United States under the name Wixela Inhub, using the same two active ingredients in matching strengths. Other inhaled corticosteroid and LABA combinations, such as budesonide with formoterol or mometasone with formoterol, treat the same general conditions but use different corticosteroid and bronchodilator molecules, have different onset characteristics, and may use different inhaler mechanics. Switching between them is therefore a clinical decision rather than a simple substitution. Anyone comparing maintenance options can also browse our Asthma category.

Safety, Interactions, and Monitoring

The inhalation powder in Advair Diskus contains lactose, which may carry trace milk proteins. This makes the product contraindicated for anyone with severe hypersensitivity to milk proteins, a different and more serious concern than routine lactose intolerance. It should not be started as the primary treatment for status asthmaticus or another acute episode requiring intensive measures. Known hypersensitivity to fluticasone, salmeterol, or another ingredient is also a contraindication.

Common adverse effects include throat irritation, hoarseness, headache, and oral thrush. Seek prompt medical attention for paradoxical bronchospasm immediately after inhalation, a severe allergic reaction, worsening breathing, chest pain, or a rapid or irregular heartbeat. The corticosteroid component can contribute to adrenal suppression, reduced bone mineral density, glaucoma, cataracts, and, in children, reduced growth velocity with prolonged exposure. Pneumonia is an important risk to watch for in people using the medicine for COPD. Clinicians may monitor symptom control, rescue-inhaler use, lung function, growth in children, bone health in at-risk patients, and eye health during long-term treatment.

The salmeterol component can raise heart rate and blood glucose, so caution and periodic monitoring are advised for people with diabetes, cardiovascular disease, seizure disorders, or thyroid disorders. Strong CYP3A4 inhibitors, such as ketoconazole or ritonavir, can meaningfully increase systemic exposure and adverse-effect risk. Other long-acting beta-agonists should not be used at the same time. Beta-blockers can reduce salmeterol's effect and may provoke bronchospasm, while non-potassium-sparing diuretics can worsen potassium or heart-rhythm effects. Monoamine oxidase inhibitors and tricyclic antidepressants also require caution, including when taken within the preceding two weeks. Pregnant or breastfeeding individuals should discuss ongoing use with a clinician because the benefits of maintaining disease control must be weighed against potential fetal or infant exposure. Current US prescribing information does not identify driving impairment as an expected effect.

Storage and Handling

Advair Diskus should be stored at room temperature between 68°F and 77°F, in a dry place away from direct heat or sunlight. The device stays inside its sealed foil pouch until first use because exposure to moisture can affect dose delivery once it is removed. After removal from the pouch, the inhaler should be discarded one month later or once the dose counter reads "0," whichever happens first, even if it feels as though powder remains.

Ordering Advair Diskus From Us

Fluticasone and salmeterol inhalation powder is classified as a prescription medicine in the United States and should be used under a prescriber's direction. Customers should select the strength and pack size that match their prescription and follow the documentation instructions displayed during our current checkout process. Our team can explain the ordering steps and help confirm that the selected listing matches the prescribed strength and quantity.

We have operated Drugs-24h since 2008, and our support team, including pharmacists, is available 24/7 by email, online chat, or phone. We can assist with product and storage questions or help track an order through packing and dispatch.